Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 11/20 | 0.63 |
| ▸ | JAK3 | P52333 | 9/20 | 0.63 |
| ▸ | JAK1 | P23458 | 5/20 | 0.63 |
| ▸ | TYK2 | P29597 | 2/20 | 0.56 |
| ▸ | BTK | Q06187 | 2/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | FLT3 | P36888 | 1/20 | 0.49 |
| ▸ | BLK | P51451 | 1/20 | 0.49 |
| ▸ | PLK4 | O00444 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15465840 | 1.00 | JAK2 (0.63) | JAK2JAK3JAK1TYK2BTK | |
| SCHEMBL13170033 | 0.93 | JAK2 (0.56) | JAK2JAK3JAK1TYK2BTK | |
| SCHEMBL15466582 | 0.93 | JAK2 (0.56) | JAK2JAK3JAK1TYK2BTK | |
| SCHEMBL15466073 | 0.92 | JAK2 (0.55) | JAK2JAK3JAK1TYK2BTK | |
| SCHEMBL13170120 | 0.92 | JAK2 (0.55) | JAK2JAK3JAK1TYK2BTK | |
| SCHEMBL15466758 | 0.92 | JAK2 (0.55) | JAK2JAK3JAK1TYK2BTK | |
| SCHEMBL13170142 | 0.92 | JAK2 (0.55) | JAK2JAK3JAK1TYK2BTK | |
| SCHEMBL13170148 | 0.92 | JAK2 (0.55) | JAK2JAK3JAK1TYK2BTK | |
| SCHEMBL13169547 | 0.90 | JAK3 (0.61) | JAK2JAK3JAK1TYK2BTK | |
| SCHEMBL13169674 | 0.89 | JAK2 (0.55) | JAK2JAK3JAK1TYK2BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040549-B2 | Thiopyrimidine-based compounds and uses thereof | YM BIOSCIENCES AUSTRALIA PTY LTD. (US) | 2015-05-26 | — | — | US | disclosed |
| US-20140051703-A1 | THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF | CYTOPIA RESEARCH PTY LTD. (AU) | 2014-02-20 | — | — | US | disclosed |
| US-20140045848-A1 | THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF | CYTOPIA RESEARCH PTY LTD. (AU) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045848-A1 | THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF | JAK3, JAK1, JAK2 | JAK2 3/4885JAK3 1/4885JAK1 2/4885 |
| US-20140051703-A1 | THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF | JAK3, JAK1, JAK2 | JAK2 3/4885JAK3 1/4885JAK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.